Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.
J Bone Miner Res. 2012 Apr;27(4):835-47. doi: 10.1002/jbmr.1543.
Bisphosphonates are widely used antiresorptive drugs that bind to calcium. It has become evident that these drugs have differing affinities for bone mineral; however, it is unclear whether such differences affect their distribution on mineral surfaces. In this study, fluorescent conjugates of risedronate, and its lower-affinity analogues deoxy-risedronate and 3-PEHPC, were used to compare the localization of compounds with differing mineral affinities in vivo. Binding to dentine in vitro confirmed differences in mineral binding between compounds, which was influenced predominantly by the characteristics of the parent compound but also by the choice of fluorescent tag. In growing rats, all compounds preferentially bound to forming endocortical as opposed to resorbing periosteal surfaces in cortical bone, 1 day after administration. At resorbing surfaces, lower-affinity compounds showed preferential binding to resorption lacunae, whereas the highest-affinity compound showed more uniform labeling. At forming surfaces, penetration into the mineralizing osteoid was found to inversely correlate with mineral affinity. These differences in distribution at resorbing and forming surfaces were not observed at quiescent surfaces. Lower-affinity compounds also showed a relatively higher degree of labeling of osteocyte lacunar walls and labeled lacunae deeper within cortical bone, indicating increased penetration of the osteocyte canalicular network. Similar differences in mineralizing surface and osteocyte network penetration between high- and low-affinity compounds were evident 7 days after administration, with fluorescent conjugates at forming surfaces buried under a new layer of bone. Fluorescent compounds were incorporated into these areas of newly formed bone, indicating that "recycling" had occurred, albeit at very low levels. Taken together, these findings indicate that the bone mineral affinity of bisphosphonates is likely to influence their distribution within the skeleton.
双膦酸盐是广泛应用的抗吸收药物,与钙结合。显然,这些药物对骨矿物质的亲和力不同;然而,尚不清楚这种差异是否会影响它们在矿物质表面的分布。在这项研究中,使用了利塞膦酸盐、其低亲和力类似物脱氧利塞膦酸盐和 3-PEHPC 的荧光缀合物,来比较具有不同矿物质亲和力的化合物在体内的定位。体外与牙本质的结合证实了化合物之间在矿物质结合上的差异,这种差异主要受母体化合物的特性影响,但也受荧光标记物的选择影响。在生长中的大鼠中,所有化合物在给药后 1 天,都优先结合在皮质骨的形成内皮层,而不是吸收的骨膜表面。在吸收表面,低亲和力的化合物优先结合在吸收陷窝中,而亲和力最高的化合物显示出更均匀的标记。在形成表面,发现进入矿化类骨质的渗透与矿物质亲和力呈反比。在吸收和形成表面没有观察到这些分布差异在静止表面。低亲和力的化合物也显示出更高程度的骨细胞陷窝壁和标记的陷窝在皮质骨内更深的标记,表明骨细胞管腔网络的穿透增加。给药后 7 天,高亲和力和低亲和力化合物在矿化表面和骨细胞网络穿透方面也存在类似的差异,形成表面的荧光化合物被新形成的骨层覆盖。荧光化合物被整合到这些新形成的骨区域中,表明发生了“再循环”,尽管水平非常低。总之,这些发现表明双膦酸盐的骨矿物质亲和力可能影响它们在骨骼中的分布。